425: NLS Pharmaceutics to Merge with Kadimastem in Share Exchange Deal

NLS Pharmaceutics will merge with Kadimastem, with Kadimastem shareholders expected to own 80% of the combined company on a fully diluted basis.

Summary

• NLS Pharmaceutics Ltd. (NLSP) has entered into a merger agreement with Kadimastem Ltd. (KDST) where Kadimastem will merge into a subsidiary of NLS Pharmaceutics.
• Kadimastem shareholders are estimated to hold 80% of the issued and outstanding shares of the combined entity on a fully diluted basis, subject to adjustments at closing.
• Following the merger, NLS Pharmaceutics intends to sell its legacy assets, with proceeds distributed to shareholders and warrantholders of NLS Pharmaceutics prior to the merger via a Contingent Value Right (CVR).
• The merger is subject to customary closing conditions, including shareholder approval from both companies and a minimum cash requirement of $600,000 for NLS Pharmaceutics and $3,500,000 for Kadimastem.
• The agreement includes termination clauses, with NLS Pharmaceutics required to pay Kadimastem a $10,000,000 termination fee plus operating and transaction expenses under certain circumstances.
• Upon closing, Kadimastem's officers and board members are expected to become the officers and board members of NLS Pharmaceutics, except for Mr. Alexander Zwyer who will remain on the board and nominate another individual to the board.
• The merger agreement anticipates closing by January 31, 2025.

Sentiment

Score: 7

Explanation: The document presents a strategic business move with potential benefits for both companies. The sentiment is cautiously optimistic, reflecting the inherent risks and uncertainties associated with mergers and acquisitions, but also the potential for value creation.

Positives

• Kadimastem shareholders are estimated to hold 80% of the issued and outstanding shares of the combined entity on a fully diluted basis, subject to adjustments at closing.
• NLS Pharmaceutics plans to divest its legacy assets after the merger, distributing the proceeds to pre-merger shareholders and warrantholders through a CVR.
• Kadimastem's management will largely replace NLS Pharmaceutics' management post-merger, with Alexander Zwyer remaining on the board.

Negatives

• NLS Pharmaceutics will pay a $10,000,000 termination fee to Kadimastem under specific termination scenarios.
• The merger is conditional on shareholder approvals and minimum cash balances of $600,000 for NLSP and $3,500,000 for KDST.

Risks

• The merger is subject to shareholder approval from both companies.
• Failure to meet minimum cash requirements of $600,000 for NLS Pharmaceutics and $3,500,000 for Kadimastem could impede the merger.
• Regulatory or legal challenges could delay or prevent the merger.
• Unexpected costs, charges, or expenses resulting from the transaction could adversely affect the combined company.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger.

Future Outlook

The document outlines the expected completion of the merger by January 31, 2025, contingent on shareholder and regulatory approvals. Post-merger, NLS Pharmaceutics intends to divest its legacy assets and distribute the proceeds to existing shareholders and warrantholders.

Management Comments

• The document does not contain direct quotes, but it implies that the boards of directors of both companies have approved the merger and recommend shareholder approval.

Industry Context

This announcement reflects a trend of consolidation within the pharmaceutical and biotechnology industries, where companies merge to leverage synergies, expand product pipelines, and gain access to new technologies or markets. The merger allows NLS Pharmaceutics to pivot its business focus while providing Kadimastem with access to public markets and potentially greater resources.

Comparison to Industry Standards

• The structure of this merger, with existing shareholders receiving contingent value rights (CVRs) tied to the sale of legacy assets, is a relatively common mechanism used in the pharmaceutical industry to bridge valuation gaps and align incentives.
• Similar deals include Sanofi's acquisition of Genzyme, where CVRs were used to incentivize the development and commercialization of specific pipeline assets.
• The 80% ownership stake for Kadimastem shareholders is a significant portion, indicating a substantial contribution of assets or value by Kadimastem to the combined entity.
• Comparable transactions often involve reverse mergers, where a private company merges into a publicly listed shell company to expedite the public listing process.

Management Changes

Stakeholder Impact

• Shareholders of Kadimastem will receive shares in NLS Pharmaceutics, potentially benefiting from the combined entity's future performance.
• Shareholders and warrantholders of NLS Pharmaceutics prior to the merger will receive CVRs, entitling them to proceeds from the sale of legacy assets.
• Employees of both companies may experience changes in roles and responsibilities following the merger.
• Customers and partners of both companies may see changes in product offerings and business relationships.

Next Steps

• Obtain shareholder approval from both NLS Pharmaceutics and Kadimastem.
• Secure necessary regulatory approvals.
• Finalize the Contingent Value Right (CVR) agreement.
• Complete the delisting of Kadimastem from the Tel Aviv Stock Exchange (TASE).
• Close the merger transaction by January 31, 2025.

Key Dates

Keywords

merger, Kadimastem, NLS Pharmaceutics, share exchange, contingent value right, legacy assets, shareholder approval, acquisition